Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of E2007 (perampanel) in patients with painful diabetic neuropathy (PDN) or post-herpetic neuralgia (PHN).

Next Previous
X
Search
Trial Profile

A multi-center, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of E2007 (perampanel) in patients with painful diabetic neuropathy (PDN) or post-herpetic neuralgia (PHN).

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 21 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perampanel (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eisai Co Ltd; Eisai Inc

    • Most Recent Events

    • 11 Apr 2019 This trial has been completed in Hungary, according to European Clinical Trials Database.
    • 15 Mar 2012 This trial is recruiting in Hungary and England.
    • 15 Mar 2012 Additional locations (England, Germany, Hungary, Lithuania) added as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top